PH80 NASAL SPRAY


Associated tags: Brain, Hot, Menopause, Neuron, MOA, Migraine, Dysmenorrhea, PMDD, Health, Mental Health, Clinical trial, SAD, Psychiatry, Social anxiety disorder, Premenstrual dysphoric disorder, Signs and symptoms, DSM-IV codes, Anxiety, ADAA, Depression, Conference, Biotechnology, Pharmaceutical, Clinical Trials, FDA, Publication

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Conference, Depression, ADAA, Anxiety, Clinical trial, DSM-IV codes, Signs and symptoms, Premenstrual dysphoric disorder, Social anxiety disorder, Psychiatry, SAD, Publication

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.
  • Title: PH80 Nasal Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder: Results from a Phase 2a Study
    The posters will be available on the Publications page of Vistagen’s website on Monday, April 15, 2024.
  • In addition to presenting fasedienol and PH80 clinical data, Vistagen will receive the ADAA 2024 Partner Recognition Award, recognizing Vistagen as a partner organization that has consistently contributed to the success of ADAA’s annual conference and supported ADAA’s public and professional mission.
  • Vistagen and ADAA are committed to redefining the future of mental health care and bringing hope to millions of individuals affected by debilitating mental health disorders.